ARIX Arix Bioscience

Corporate update from portfolio company Harpoon Therapeutics

Arix Bioscience PLC (ARIX)
Corporate update from portfolio company Harpoon Therapeutics

14-March-2022 / 11:32 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 

PRESS RELEASE

 

Arix Bioscience plc

 

Corporate update from portfolio company Harpoon Therapeutics

 

LONDON, 14 March 2022: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, notes the recent announcement from Harpoon Therapeutics, Inc. (Nasdaq: HARP) of its financial results for the fourth quarter and full year of 2021, in which the company provided a corporate update.

 

Following a thorough analysis of its HPN424 data, including clinical results to date, the company decided to discontinue the phase 1/2 dose escalation study for HPN424 in patients with metastatic castration-resistant prostate cancer. The discontinuation will allow Harpoon to concentrate on HNP328, in development for tumours associated with delta like ligand 3 (DLL3) expression, and HPN 217 for BCMA.

 

Earlier in March, Harpoon announced the granting of Orphan Drug Designation for HPN328 in small cell lung cancer and Fast Track designation for HPN2178 in relapsed, refractory multiple myeloma. Studies to determine the recommended phase 2 dose for both candidates are expected to complete this year.

 

The full text of the Harpoon announcement can be accessed .

 

 

[ENDS]

 

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil

+44 (0)20 7250 1446

 

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.


ISIN: GB00BD045071
Category Code: PFU
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 148920
EQS News ID: 1301829

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1301829&application_name=news&site_id=research_pool
EN
14/03/2022

Underlying

ARIXArix Bioscience

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arix Bioscience

ECK ECKOH
TYM Tertiary Minera... ... (+9)

Hybridan Small Cap Feast - 12 Feb 24

12th February 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj...

ECK ECKOH
TYM TERTIARY MINERALS PLC
GOOD GOOD ENERGY GROUP
VAL VALIRX
DCTA DIRECTA PLUS
ARIX ARIX BIOSCIENCE
JNEO JOURNEO PLC
POLB POOLBEG PHARMA PLC
ECR ECR MINERALS PLC
02/12/24 February 12, 2024 1 EN
 PRESS RELEASE
Free
ARIX ARIX BIOSCIENCE

Scheme Effective

Arix Bioscience PLC (ARIX) Scheme Effective 12-Feb-2024 / 12:00 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. FOR IMMEDIATE RELEASE Legal En...

February 12, 2024 1 EN
 PRESS RELEASE
Free
ARIX ARIX BIOSCIENCE

Suspension of Trading in Shares

Arix Bioscience PLC (ARIX) Suspension of Trading in Shares 12-Feb-2024 / 07:00 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. FOR IMMEDIATE RE...

February 12, 2024 1 EN
 PRESS RELEASE
Free
ARIX ARIX BIOSCIENCE

Transaction Update

Arix Bioscience PLC (ARIX) Transaction Update 07-Feb-2024 / 11:30 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. FOR IMMEDIATE RELEASE Legal ...

February 7, 2024 1 EN
 PRESS RELEASE
Free
ARIX ARIX BIOSCIENCE

Results of First General Meeting

Arix Bioscience PLC (ARIX) Results of First General Meeting 29-Jan-2024 / 12:15 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. FOR IMMEDIATE R...

January 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch